XS
SRPT icon

XR Securities’s Sarepta Therapeutics SRPT Stock Holding History

XR Securities’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,300
Closed -$263K – 430
2023
Q2 		$263K Sell
2,300
-100
-4% -$12.9K 0.01% 302
2023
Q1 		$331K Buy
+2,400
New +$311K 0.01% 307
2019
Q1 		– Sell
-5,000
Closed -$278K – 402
2018
Q4 		$278K Hold
5,000
– – 0.12% 109
2018
Q3 		$541K Buy
+5,000
New +$684K 0.14% 88

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

XR Securities's SRPT Position: Q1 2021 in Review

XR Securities sold out of Sarepta Therapeutics (SRPT) in Q1 2021, closing a stake of 1,373 shares — an estimated $234K sold.

XR Securities first reported a position in SRPT in Q2 2018 and held it in 2 quarters. The position peaked at $248K in Q2 2018. 366 funds tracked by Wall St. Rank hold SRPT as of Q1 2021.

  • XR Securities reported no remaining Sarepta Therapeutics position as of Q1 2021 after selling out during the quarter.
  • XR Securities sold 1,373 Sarepta Therapeutics shares in Q1 2021, an estimated $234K.
  • XR Securities first reported a position in Sarepta Therapeutics in Q2 2018 and held it in 2 quarters.
  • XR Securities's Sarepta Therapeutics position peaked at $248K in Q2 2018.
  • 366 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2021.

Based on XR Securities's 13F filing for Q1 2021, filed 29 Apr 2021.